Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HTR5A | P47898 | 1/20 | 0.63 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 8/20 | 0.50 |
| ▸ | HTR2C | P28335 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5682360 | 0.98 | LMNA (0.62) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL30228634 | 0.89 | TAAR1 (0.59) | LMNACYP1A2CYP2D6THRBALOX15 | |
| Hydrochloric Acid SCHEMBL8508190 | 0.87 | TAAR1 (0.62) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL30228791 | 0.84 | ROCK2 (0.47) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL25425215 | 0.82 | LMNA (0.62) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL7818620 | 0.82 | LMNA (0.67) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL2969878 | 0.82 | LMNA (0.62) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL1798062 | 0.82 | LMNA (0.62) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL30685317 | 0.82 | LMNA (0.62) | LMNACYP1A2CYP2D6THRBALOX15 | |
| SCHEMBL1872944 | 0.82 | MAPT (0.64) | LMNACYP1A2CYP2D6THRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110223166-A1 | Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death | MINAS THEODORE CORONEO (AU) | 2011-09-15 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-7084154-B2 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA DRUG DISCLOVERY, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060013814-A1 | Methods for preventing pressure-induced apoptotic neural-cell death | DAVIES COLLISON CAVE (AU) | 2006-01-19 | — | — | US | disclosed |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA, INC (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004071445-A2 | 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-5304379-A | A reservoir consists of tetracaine and metabolic modulator to inhibit monoamine oxidase enzyme | ALZA CORPORATION (US) | 1994-04-19 | — | — | US | disclosed |
| US-4885154-A | COADMINISTERING A METABOLIC MODULATOR | ALZA CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0331391-A1 | Method for reducing sensitization or irritation in transdermal drug delivery and means therefor | ALZA CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | LMNA 3390/4885CYP1A2 62/4885CYP2D6 49/4885 |
| US-20060013814-A1 | Methods for preventing pressure-induced apoptotic neural-cell death | BAX, CASP3, BCL2 | LMNA 233/4885CYP1A2 4872/4885CYP2D6 4867/4885 |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | OPRL1, OPRM1, OPRK1 | LMNA 4524/4885CYP1A2 18/4885CYP2D6 40/4885 |
| US-20110223166-A1 | Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death | BAX, CASP3, BCL2 | LMNA 233/4885CYP1A2 4872/4885CYP2D6 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.